Support NCODA’s Patient-Centered Initiatives
NCODA News
- FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- Bortezomib (Velcade) Management for Multiple Myeloma and Mantle Cell Lymphoma
- AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
2021 Spring Forum
ONCOLYTICS TODAY SPRING 2021 ISSUE AVAILABLE NOW!
Contact
P.O. Box 468
Cazenovia, NY 13035
contact@ncoda.org
315-655-4640
a 501(c)(3) Organization
Passion for Patients
- 315-655-4640
- contact@ncoda.org